42nd week of 2008 patent applcation highlights part 35 |
Patent application number | Title | Published |
20080253943 | Method for vapor phase catalytic oxidation - An object of the present invention is to provide a method for vapor phase catalytic oxidation which is almost free of variations in reaction states in respective reaction tubes of the fixed bed multi-tube heat-exchanger type reactor. | 2008-10-16 |
20080253944 | METHOD AND SYSTEM FOR INTRODUCING FUEL OIL INTO A STEAM REFORMER WITH REDUCED CARBON DEPOSITION - A system and method for creating reformate with decreased carbon deposition. The system is made up of a steam source, a superheater, a fuel injection device, a prereformer, and a reformer with catalyst linings. The system functions to superheat steam while maintaining the fuel at a lower temperature prior to injection and mixing with the steam. After injection and mixing, the steam and fuel mixture is then passed through a prereformer where catalysts treat a portion of the fuel and steam mixture. After these portions are treated with a catalyst, the mixture is passed through to a reformer where further treatment of the material by catalyst takes place. | 2008-10-16 |
20080253945 | Production of Synthetic Rutile by Continuous Leaching | 2008-10-16 |
20080253946 | Autoclave - A waste treatment apparatus having an autoclave that includes a pressure vessel ( | 2008-10-16 |
20080253947 | CORNER PROTECTOR FOR PREVENTING TEARING OF STERILIZATION WRAP WRAPPED AROUND A STERILIZATION TRAY - A sterilization wrap protector separates a sterilization tray from a sterilization wrap, the protector may include a foam plastic material having an inside engagement surface. The inside engagement surface may include a first inside surface that is generally planar, a second inside surface which extends from the first inside surface and that is generally arcuate in cross section and a third inside surface which also extends from the first inside surface and is also generally arcuate in cross section. An outside engagement surface may include a first outside surface that is generally planar, a second outside surface that is generally planar and which extends in a direction that is generally perpendicular to the first outside surface and a third outside surface that is generally planar and which extends in a direction that is generally perpendicular to the first outside surface and to the second outside surface. | 2008-10-16 |
20080253948 | METHOD FOR THE RECYCLING AND PURIFICATION OF AN INORGANIC METALLIC PRECURSOR - Methods and apparatus for the recycling and purification of an inorganic metallic precursor. A first gaseous stream containing ruthenium tetroxide is provided, and transformed into a solid phase lower ruthenium oxide. This lower phase ruthenium oxide is reduced with hydrogen to form ruthenium metal. The ruthenium metal is contacted with an oxidizing mixture to produce a stream containing ruthenium tetroxide, and any remaining oxidizing compounds are removed from this stream through a distillation. | 2008-10-16 |
20080253949 | PROCESS FOR REMOVING SULFUR FROM A FUEL GAS STREAM - A process for removing organic sulfur from a fuel gas stream that further contains light olefins by catalytic hydrodesulfurization to yield a treated fuel gas having an very low concentration of organic sulfur. The effluent of the catalytic hydrodesulfurization reactor may be cooled with a portion thereof being recycled and introduced along with the fuel gas stream that is charged to the hydrodesulfurization reactor. The remaining, unrecycled portion of the effluent may further be treated to remove the hydrogen sulfide that is yielded from by the hydrodesulfurization of the fuel gas stream. | 2008-10-16 |
20080253950 | HYDROTHERMALLY STABLE AG-ZEOLITE TRAPS FOR SMALL OLEFIN HYDROCARBON MOLECULES - A hydrocarbon trap comprises an Ag-zeolite which is heated by a unique steaming regimen. | 2008-10-16 |
20080253951 | PHOSPHOR - A phosphor is provided. The phosphor includes a composition represented by the formula: M | 2008-10-16 |
20080253952 | FLUORESCENT SUBSTANCE CONTAINING NITROGEN, METHOD FOR MANUFACTURING THE SAME, AND LIGHT-EMITTING DEVICE - Disclosed is a method for manufacturing a nitrogen-containing fluorescent substance comprising accommodating an oxide fluorescent substance containing two or more elements in a receptacle made of a material containing carbon, and sintering the oxide fluorescent substance in a mixed gas atmosphere containing nitrogen gas. | 2008-10-16 |
20080253953 | Silicate Producing Method - The present invention relates to a process for the preparation of a silicate comprising at least silicon and oxygen, comprising
| 2008-10-16 |
20080253954 | METHOD FOR PRODUCING POWDER FORSTERITE POWDER, FORSTERITE POWDER, SINTERED FORSTERITE, INSULATING CERAMIC COMPOSITION, AND MULTILAYER CERAMIC ELECTRONIC COMPONENT - A forsterite powder with superior characteristics which can be sintered at a relatively low temperature can be economically produced, when a magnesium source, a silicon source, and copper particles are mixed to prepare a mixed powder containing 300 to 2,000 ppm by weight of the copper particles, and the mixed powder is fired. The magnesium source used is preferably Mg(OH) | 2008-10-16 |
20080253955 | Process and apparatus for purifying low-grand silicon material - A process and apparatus for purifying low-purity silicon material and obtaining a higher-purity silicon material is provided. The process includes providing a melting apparatus equipped with an oxy-fuel burner, and melting the low-purity silicon material in the melting apparatus to obtain a melt of higher-purity silicon material. The melting apparatus may include a rotary drum furnace and the melting of the low-purity silicon material may be carried out at a temperature in the range from 1410° C. to 1700° C. under an oxidizing or reducing atmosphere. A synthetic slag may be added to the molten material during melting. The melt of higher-purity silicon material may be separated from a slag by outpouring into a mould having an open top and insulated bottom and side walls. Once in the mould, the melt of higher-purity silicon material can undergo controlled unidirectional solidification to obtain a solid polycrystalline silicon of an even higher purity. | 2008-10-16 |
20080253956 | Process and system for producing commercial quality carbon dioxide from high solids lime mud - The invention features methods and systems for producing commercial quality carbon dioxide (CO | 2008-10-16 |
20080253957 | Process and Plant for Producing Sulfuric Acid - There are described a process and a plant for producing sulfuric acid by catalytic oxidation of SO | 2008-10-16 |
20080253958 | PRODUCTION OF HIGH-PURITY TITANIUM MONOXIDE AND CAPACITOR PRODUCTION THEREFROM - The present invention relates to high-purity titanium monoxide powder (TiO) produced by a process of combining a mixture of titanium suboxides and titanium metal powder or granules; reacting the mixture at a temperature above about 1200° C.; and fragmenting the body to form TiO particles suitable for application as e.g., capacitors. The TiO product is unusually pure in composition and crystallography, highly dense, and can be used for capacitors and for other electronic applications. The method of production of the TiO is robust, does not require high-purity feedstock, and can reclaim value from waste streams associated with the processing of TiO electronic components. | 2008-10-16 |
20080253959 | Synthesis crystalline molecular sieves - In a process for synthesizing a crystalline molecular sieve, an aqueous synthesis mixture is produced capable of forming the crystalline molecular sieve. Crystallization of the synthesis mixture is induced so as to form crystals of said molecular sieve in the synthesis mixture and, when crystallization is complete, the molecular sieve crystals are allowed or caused to separate from the remainder of the synthesis mixture to produce a solid phase comprising said molecular sieve crystals and a supernatant liquid phase. The supernatant liquid phase is then decanted from the solid phase to recover the molecular sieve crystals and the crystals are dried without initially being subjected to washing or filtration. | 2008-10-16 |
20080253960 | Lipoprotein-Based Nanoplatforms - The present invention provides a non-naturally occurring lipoprotein nanoplatform (“LBNP”) comprising at least one cell surface receptor ligand; at least one lipoprotein; and at least one diagnostic agent and/or at least one therapeutic agent. In embodiments of the present invention, the cell surface receptor ligand is not a low-density lipoprotein receptor ligand and the cell surface receptor ligand is covalently bonded to the apoprotein. The present invention also provides pharmaceutical formulations comprising LBNPs and methods of making the LBNPs. | 2008-10-16 |
20080253961 | Formulation of Active Agent Loaded Activated PLGA Nanoparticles for Targeted Cancer Nano-Therapeutics - The present invention includes compositions and methods of making an activated polymeric nanoparticle for targeted drug delivery that includes a biocompatible polymer and an amphiphilic stabilizing agent non-covalently associated with a spacer compound that includes at least one electrophile that selectively reacts with any nucleophilic on a targeting agent and places the targeting agent on the exterior surface of a biodegradable nanoshell, wherein an active agent is loaded with the nanoshell. | 2008-10-16 |
20080253962 | Irta-4 Antibodies and Their Uses - The present invention provides isolated monoclonal antibodies, particularly human monoclonal antibodies, that specifically bind to IRTA-4 with high affinity. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for detecting IRTA-4, as well as methods for treating various B cell malignancies, including non-Hodgkin's lymphoma. | 2008-10-16 |
20080253963 | Tumor markers in ovarian cancer - The present invention features methods of diagnosing and prognosticating ovarian tumors by detecting increased expression of an ovarian tumor marker gene in a subject or in a sample from a subject. Also featured are kits for the aforementioned diagnostic and prognostic methods. In addition, the invention features methods of treating and preventing ovarian tumors, and methods of inhibiting the growth or metastasis of ovarian tumors, by modulating the production or activity of an ovarian tumor marker polypeptide. Further featured are methods of inhibiting the growth or metastasis of an ovarian tumor by contacting an ovarian tumor cell with an antibody that specifically binds an ovarian tumor marker polypeptide. | 2008-10-16 |
20080253964 | Methods and Compositions for F-18 Labeling of Proteins, Peptides and Other Molecules - The present application discloses compositions and methods of synthesis and use of F-18 labeled molecules of use, for example, in PET imaging techniques. In particular embodiments, the labeled molecules may be peptides or proteins, although other types of molecules including but not limited to aptamers, oligonucleotides and nucleic acids may be labeled and utilized for such imaging studies. In preferred embodiments, the F-18 label may be conjugated to a targeting molecule by formation of a metal complex and binding of the F-18-metal complex to a chelating moiety, such as DOTA, NOTA, DTPA, TETA or NETA. In other embodiments, the metal may first be conjugated to the chelating group and subsequently the F-18 bound to the metal. In other preferred embodiments, the F-18 labeled moiety may comprise a targetable conjugate that may be used in combination with a bispecific or multispecific antibody to target the F-18 to an antigen expressed on a cell or tissue associated with a disease, medical condition, or pathogen. Exemplary results show that F-18 labeled targetable conjugate peptides are stable in human serum at 37° C. for several hours, sufficient time to perform PET imaging analysis. | 2008-10-16 |
20080253965 | Small-Molecule Hsp90 Inhibitors - Hsp90 inhibitors are provided having the formula: | 2008-10-16 |
20080253966 | Diagnostic, Prognostic, and Therapeutic Factor Smac/Diablo in Human Cancer - The present invention provides, for the first time, the finding that Smac/DIABLO is underexpressed in cancers such as renal cell carcinoma. In particular, the present invention provides methods of diagnosing and providing a prognosis for cancers that underexpress Smac/DIABLO, as well as methods of drug discovery to identify therapeutics useful when used alone or in combination with other cancer therapeutics. The present invention also provides methods of treating or inhibiting cancers that underexpresses Smac/DIABLO, in which potentiation of Smac/DIABLO expression and/or activity sensitizes resistant tumor cells to cytotoxic treatments including chemotherapy, radiation therapy, hormonal therapy, and immunotherapy. Compositions, kits, and integrated systems for carrying out the diagnostic, prognostic, and therapeutic methods of the present invention are also provided. | 2008-10-16 |
20080253967 | Halo-Stilbene Derivatives And Their Use For Binding And Imaging Of Amyloid Plaques - This invention relates to a method of imaging amyloid deposits and to styrylpyridine compounds, and methods of making radiolabeled styrylpyridine compounds useful in imaging amyloid deposits. This invention also relates to compounds, and methods of making compounds for inhibiting the aggregation of amyloid proteins to form amyloid deposits, and a method of delivering a therapeutic agent to amyloid deposits. | 2008-10-16 |
20080253968 | IN VIVO EXAMINATION METHOD - It is possible to perform quantitative examination of biological tissue even with a solution composed of a near-infrared fluorescent dye and a polypeptide. An image acquired before administering a reagent is subtracted from an image acquired after administering the reagent to remove regions appearing in both images, such as autofluorescence, thus obtaining an image in which only detected fluorescence affected by administration of the reagent is extracted. Because tumors have many (leaky) blood vessels, regions having many areas of high intensity in the extracted image can be recognized as tumors. | 2008-10-16 |
20080253969 | MULTI-FUNCTIONAL POLYGLUTAMATE DRUG CARRIERS - Various biodegradable polyglutamate polymer conjugates that can include recurring units of the general formulae (I) and (II) are described herein. Such polymer conjugates are useful for variety of drug, targeting, stabilizing and/or imaging agent delivery applications. | 2008-10-16 |
20080253970 | Stable Pharmaceutical Drug Products - Various aspects of the present invention provide for methods of manufacturing a pharmaceutical drug product, which include storing a container at a temperature greater than ambient conditions for at least about seven days and conducting release testing on the container after storing. Products manufactured by this method have a more consistent fine particle size distribution (FSD) and fine particle fraction (FPF) at ambient conditions and at accelerated stability conditions over the life of the drug product. Advantageously, such products may more reliably and regularly pass testing requirements as required for an approved drug product by regulatory authorities such as the United States Food and Drug Administration (USFDA). | 2008-10-16 |
20080253971 | Particles for inhalation having sustained release properties - The invention generally relates to a method for pulmonary delivery of therapeutic, prophylactic and diagnostic agents to a patient wherein the agent is released in a sustained fashion, and to particles suitable for use in the method. In particular, the invention relates to a method for the pulmonary delivery of a therapeutic, prophylactic or diagnostic agent comprising administering to the respiratory tract of a patient in need of treatment, prophylaxis or diagnosis an effective amount of particles comprising a therapeutic, prophylactic or diagnostic agent or any combination thereof in association with a charged lipid, wherein the charged lipid has an overall net charge which is opposite to that of the agent upon association with the agent. Release of the agent from the administered particles occurs in a sustained fashion. | 2008-10-16 |
20080253972 | Aqueous/alcoholic deodorant composition comprising a water-soluble zinc salt and salicylic acid - The present disclosure relates to a deodorant composition comprising, in a cosmetically acceptable medium: a) at least one water-soluble zinc salt; b) salicylic acid; c) at least one C | 2008-10-16 |
20080253973 | SENSATION MODIFYING TOPICAL COMPOSITION FOAM - This invention relates to foamable compositions that are capable of producing a sensation or sensation modifying effect upon application on a body surface. More particularly the invention relates to foamable pharmaceutical, therapeutic and cosmetic compositions, comprising an active agent, having a sensation or sensation modifying affect on a body surface, upon application. More particularly, the invention relates to foamable compositions comprising: (a) a foamable carrier; (b) at least one sensation or sensation modifying agent, selected from the group of a cooling agent; a warming agent; a relaxing or soothing agent; stimulating or refreshing agent; or mixtures thereof and (c) a propellant at a concentration of about 3% to about 45% by weight of the total composition. The foamable carrier can be an emollient emulsion foamable vehicle, a foamable gel vehicle and can also be a substantially non aqueous foamable vehicle. | 2008-10-16 |
20080253974 | N-Phenyl-N-Pyridinyl-Benzamides and Benzenesulfonamides Having Cooling Properties - Used as cooling agents are the compounds of formula (I), wherein Y is carbonyl (C(═O)) or sulfonyl (SO | 2008-10-16 |
20080253975 | COMPOSITION FOR DYEING DENTAL PLAQUE FOR EVALUATING DENTAL CARIES ACTIVITY - An objective of the present invention is to provide a composition for dyeing dental plaque for evaluation of dental caries activity that is capable of simultaneously dyeing dental plaque and evaluating dental caries activity, and which can evaluate thick dental plaque more accurately than the conventional technique. The composition for dyeing dental plaque for evaluation dental caries activity comprises: a blue pigment being dissolved in water and having a color tone not changing at pH 7 or less; a red pigment being dissolved in water at pH more than 4.5 but not dissolved in water at pH 4.5 or less, and having a color tone not changing at pH 4.5 or less; and sugar. The content of sugar is preferably 1 to 50 weight parts to the total of 1 weight part of contents of the blue pigment and the red pigment, and ratio of contents of the blue pigment and the red pigment is preferably 1:3 to 3:1. | 2008-10-16 |
20080253976 | Personal Care Compositions Comprising An Antimicrobial Blend of Essential Oils or Constituents Thereof - Disclosed are personal care compositions, including compositions for oral, throat and skin care comprising a blend of naturally occurring flavor or perfume ingredients or essential oils containing such ingredients, wherein the blend provides excellent antimicrobial activity and comprises at least two components, a first acyclic component selected from citral, neral, geranial, geraniol and nerol and a second cyclic-containing component selected from eucalyptol, carvacrol and eugenol. Preferably, the blend comprises 3, 4, 5 or more of the above components. Greater synergy in terms of antimicrobial efficacy may be obtained the more different components are blended together. The present compositions are effective in killing, suppressing the growth of and/or altering metabolism of microorganisms including those which cause undesirable oral cavity conditions including plaque, caries, calculus, gingivitis, periodontal disease and malodor. Optionally the blend further comprises additional antimicrobial and/or anti-inflammatory components, preferably naturally-occurring as well. | 2008-10-16 |
20080253977 | Novel plant gene and uses thereof - A novel gene isolated from | 2008-10-16 |
20080253978 | Derivatives of Pyrrolyltriazine Together with Methods for Obtaining Them and Their Use as Protecting Agents Uv Radiation - The present invention relates to new pyrrolyltriazine derivatives of general formula (I) together with method for obtaining them. The physico-chemical properties of said compounds allow them to be used as absorbents of UV radiation. | 2008-10-16 |
20080253979 | METHOD FOR THE TREATMENT OF NAIL DISEASE - A treatment for diseased nails comprises treating the diseased nail after thorough cleaning with a peroxide solution, and thereafter applying an iodine solution until the diseased nail has recovered. | 2008-10-16 |
20080253980 | Method of making up nails - The present invention is directed to a method of making up nails, the method involving: a) applying onto the nails a first composition containing: i) at least one color precursor, ii) at least one film former, iii) at least one volatile solvent, iv) optionally, at least one buffer, and v) optionally, at least one colorant; (b) applying a second composition over top of at least a portion of the first composition, the second composition containing at least one color activator; and (c) optionally, applying a third composition over top of at least a portion of the second composition, the third composition containing at least one color deactivator. | 2008-10-16 |
20080253981 | Stabilized body care products, household products, textiles and fabrics - Disclosed are stabilized body care products, household products, textiles and fabrics which comprise certain sterically hindered amine salt compounds. Dyed products and articles are effectively stabilized against color degradation. The products are for example skin-care products, hair-care products, dentifrices, cosmetics, laundry detergents and fabric softeners, non-detergent based fabric care products, household cleaners and textile-care products. | 2008-10-16 |
20080253982 | Ascorbic acid derivatives and skin-whitening cosmetics - It is an object to provide an L-ascorbic acid derivative which can keep the L-ascorbic acid stable to heat and light and thus has a long shelf life, which is high in permeability into the skin, which can be quickly hydrolyzed by phosphatase, an enzyme that is ubiquitous in vivo, and which exhibits physiological activities that are inherent to L-ascorbic acid and beneficial to health, a method for producing such an L-ascorbic acid derivative, and a skin-whitening cosmetic material. | 2008-10-16 |
20080253983 | SOS - Daily Control for Shiny and Oily Skin, Hair, Bald Scalp, and Body - When used as suggested, this invention uses Anhydrous MgSO4.7H2O as the primary substance, in liquid or solid forms, to control the appearance of shiny and oily skin, and hair; and also manages body moisture under normal situations and environmental conditions. Formulas are predetermined unit measurements to achieve or maintain the desired results. | 2008-10-16 |
20080253984 | METHODS OF INHIBITING THE GROWTH OF ONYCHOMYCOSIS AND URUSHIOL-INDUCED ALLERGIC CONTACT DERMATITIS - A method for treating onychomycosis and skin conditions such as urushiol-induced allergic contact dermatitis comprises coating the affected nail or skin with a solution comprising an at least a primary diamine with modified diphenylmethane diisocyanates and a carrier solvent/reactant. | 2008-10-16 |
20080253985 | Compositions for Lowering Serum Cholesterol and/or Triglycerides - The invention provides methods and compositions for treating hyperlipidemia and disorders associated with hyperlipidemia in a mammal. Compositions useful in the practice of the invention include a microsomal triglyceride transport protein inhibitor (“MTPI”) and at least two other cholesterol lowering drugs selected from the group consisting of a cholesterol absorption inhibitor (“CAI”), a HMG-CoA reductase inhibitor, a bile acid sequestrant, a fibric acid derivative, niacin, and squalene synthetase inhibitor. | 2008-10-16 |
20080253986 | Cosmetic/dermatological compositions comprising naphthoic acid compounds and polyurethane polymers - Cosmetic/dermatological compositions for topical application and useful for the treatment, e.g., of acne, contain, formulated into a physiologically acceptable medium, at least one naphthoic acid compound and at least one polyurethane polymer or derivative thereof, the at least one naphthoic acid compound being dispersed therein. | 2008-10-16 |
20080253987 | POLYMERIC TISSUE SEALANT - Methods for making biomaterials for use as a tissue sealant, kits containing precursors for forming the biomaterials, and the resulting biomaterials are described herein. The biomaterials are formed from a composition comprising at least a first and a second precursor molecule, wherein:
| 2008-10-16 |
20080253988 | Pyrrolo [1,2-D] [1,2-4] Triazine as Inhibitors of C-Jun N Terminal Kinases (Jnk) and P-38 Kinases - A compound of formula (I): wherein the substituents are as defined in the specification as inhibitor of C-Jun N terminal Kinases (JNK) and P-38 Kinases. | 2008-10-16 |
20080253989 | Neuron Regeneration - The invention provides a gene silencing molecule, which is adapted to down-regulate expression of a gene encoding a peptide involved with the Rho-A inhibitory pathway. The gene silencing molecule is used to promote neuron survival and axon regeneration in the central nervous system (CNS). The invention also provides compositions and methods of using same to improve neural survival and promote axonal growth. | 2008-10-16 |
20080253990 | Self-Containing Lactobacillus Strain - The invention relates to a recombinant | 2008-10-16 |
20080253991 | Anti-T Cell and Autoantigen Treatment of Autoimmune Disease - The invention is directed to a new method for the treatment of new onset Type I diabetes in mammals or for the treatment of pre-Type I diabetic mammals where the method comprises administering (a) anti-T cell therapy to the mammal and administering (b) an autoantigen and optional mucosal antigen composition, wherein (a) and (b) are administered concurrently or sequentially Exemplified is a treatment using a mixture of anti-CD3 antibodies, a glutamic acid decarboxylase (GAD) autoantigen, and an immunoregulatory cytokine Canme GAD sequences are also disclosed. | 2008-10-16 |
20080253992 | METHODS FOR THE PURIFICATION OF POLYPEPTIDE CONJUGATES - The present invention provides processes for the manufacturing of polypeptide conjugates. In particular, the invention provides methods for the purification of polypeptide conjugates, which include at least one polymeric modifying groups, such as a poly(alkylene oxide) moiety. Exemplary poly(alkylene oxide) moieties include poly(ethylene glycol) (PEG) and poly(propylene glycol). In an exemplary process, hydrophobic interaction chromatography (HIC) is used to resolve different glycoforms of glycoPEGylated polypeptides. | 2008-10-16 |
20080253993 | Immunogenic Egfr Peptides Comprising Foreign T Cell Stimulating Epitope - Disclosed is a method for inducing an immune response against autologous Epidermal Growth Factor Receptor (EGFR) in humans. The method comprises effecting uptake by antigen presenting cells of epitopes (preferably all) from the extracellular portion of human EGFR and of at least one non-human T helper epitope (T | 2008-10-16 |
20080253994 | Methods and Compositions for Contributing to the Treatment of Cancers - Methods and compositions for contributing to the treatment of cancers, especially ovarian tumors, are disclosed. The methods and compositions utilize an endothelin B agonist (ET | 2008-10-16 |
20080253995 | MODIFIED FLUORINATED NUCLEOSIDE ANALOGUES - The disclosed invention provides compositions and methods of treating a Flaviviridae infection, including hepatitis C virus, West Nile Virus, yellow fever virus, and a rhinovirus infection in a host, including animals, and especially humans, using a (2′R)-2′-deoxy-2′-fluoro-2′-C-methyl nucleosides, or a pharmaceutically acceptable salt or prodrug thereof. | 2008-10-16 |
20080253996 | Use of Sdf-1 for the Treatment and/or Prevention of Neurological Diseases - The invention relates to the use of SDF-1, or of an agonist of SDF-1 activity, for the treatment and/or prevention of a neurological disease. | 2008-10-16 |
20080253997 | COMPOSITIONS AND METHODS FOR PROTECTING CELLS FROM TOXIC EXPOSURES - The present invention provides compositions and methods for protecting cells and tissues from damage associated with therapeutic treatments of cancers and other diseases and conditions where reactive oxygen species are produced. The present invention also provides compositions useful as research reagents. | 2008-10-16 |
20080253998 | TREATMENT OF CANCER USING TLR3 AGONISTS - The present invention relates generally to the fields of genetics and medicine. More specifically, the present invention relates to improved methods of treating cancers using a TLR3 agonist, by assessing the expression of a TLR3 receptor by cancer cells. | 2008-10-16 |
20080253999 | Methods For Differentiating Stem Cells and Uses Thereof in the Treatment of Dental Conditions - The present invention relates to a method for propagating and/or differentiating mammalian cells, the method comprising exposing or co-culturing mammalian cells with one or more of periodontal ligament tissue, periodontal ligament proteins or factors derived from periodontal ligament tissue, to obtain cells having PDL characteristics and fulfilling at least one of the following:
| 2008-10-16 |
20080254000 | Methods of Improving the Yield and/or Quality of Aquatic or Marine Animals - Methods of treating aquatic or marine animal water bodies including contacting the water body with one or more sulfur oxidizing bacteria such as those selected from the genus | 2008-10-16 |
20080254001 | Novel bone mineralization protein expression systems, and methods of studying their intracellular signaling pathways - The present invention is directed to methods of switching a differentiation of a cell from a non-osteogenic lineage into an osteogenic lineage. The present invention is also directed to methods of generating a model system for assessing the intracellular signaling pathways of bone growth factors. | 2008-10-16 |
20080254002 | Bone Marrow Derived Oct3/4+ Stem Cells - The invention provides bone-marrow derived stem cells, e.g., cardiomyocyte precursor cells, differentiated cardiomyocytes generated from the precursor cells, and a method for treating cardiac dysfunction in a subject by administering such cells. | 2008-10-16 |
20080254003 | Differentiation of Human Embryonic Stem Cells and Cardiomyocytes and Cardiomyocyte Progenitors Derived Therefrom - The present invention provides a method to improve current culturing methods for the differentiation of cardiomyocytes from hES cells. The method includes culturing the hES cells in the presence of ascorbic acid or a derivative thereof. Preferably the culturing is conducted in serum free conditions. The invention also includes isolated cardiomyocytes and cardiac progenitors differentiated by the methods as well as the use of these cells in methods of treating and preventing cardiac diseases and conditions. Culture media and extracellular media are also provided which include ascorbic acid for the differentiation of hES cells to cardiomyocytes. | 2008-10-16 |
20080254004 | Homogeneous Neural Precursor Cells - This invention provides pure populations of neural precursor cells, capable of differentiation into neurons, glial cells, and astrocytes. The populations are obtained by culturing stem cell populations (such as embryonic stem cells) in a cocktail of growth conditions that initiates differentiation, and establishes the neural precursor population. The precursors can be further differentiated in culture into a variety of different neural phenotypes. The neural precursors can be generated in pure form (at least 99%) and in large quantities for use in drug screening and the treatment of neurological disorders. | 2008-10-16 |
20080254005 | Stem Cell Therapy for the Treatment of Autism and Other Disorders - Disclosed are methods, compositions of matter, and cells, useful for the treatment of autism, social integrative disorders, and various cognitive abnormalities. The invention discloses, inter alia, means of inducing angiogenesis and immune modulation either in sequence or parallel in order to substantially ameliorate or reverse the progression of autism. The use of stem cells, and cells naturally possessing or endowed with angiogenic and anti-inflammatory activity are disclosed for autism either alone or in combination with various therapeutic interventions. | 2008-10-16 |
20080254006 | TREATMENT OF ALOPECIA BY MICROPORE DELIVERY OF STEM CELLS - A method of restoring hair to skin that has suffered hair loss includes optically ablating an array of spaced-apart microchannels or voids into the skin and transplanting into the voids stem cells, a scaffold and a differentiation factor for causing the stem cells to differentiate into hair follicles. | 2008-10-16 |
20080254007 | Human Mesenchymal Progenitor Cell - The present invention provides isolated pluri-differentiated human mesenchymal progenitor cells (MPCs), which simultaneously express a plurality of genes that are markers for multiple cell lineages, wherein the multiple cell lineages comprise at least four different mesenchymal cell lineages (e.g., adipocyte, osteoblast, fibroblast, and muscle cell) and wherein each of the markers is specific for a single cell lineage. The present invention also method for isolating and purifying human mesenchymal progenitor cells from Dexter-type cultures for characterization of and uses, particularly therapeutic uses for such cells. Specifically, isolated MPCs can be used for diagnostic purposes, to enhance the engraftment of hematopoietic progenitor cells, enhance bone marrow transplantation, or aid in the treatment or prevention of graft versus host disease. | 2008-10-16 |
20080254008 | Lentiviral Vectors and Their Use - The present invention relates to lentiviral vectors for gene therapy, cancer treatment, producing recombinant proteins, such as antibodies and vaccines, and other therapeutic purposes. Novel lentiviral vectors are disclosed, e.g., comprising helper sequences in opposite orientations and/or minimally functional LTR sequences, which can be used to prepare high efficiency transduction vectors. Vectors are also designed to express silencing RNA and antisense polynucleotides. | 2008-10-16 |
20080254009 | Method of treating gastrointestinal diseases associated with species of genus clostridium - The invention includes a method of treating gastrointestinal diseases associated with species of genus | 2008-10-16 |
20080254010 | Controlling Clostridium difficile-Associated Disease in the Gastrointestinal Tract - This document provide materials and methods for treating patients infected with a spore-forming bacteria and materials and methods for preventing development of | 2008-10-16 |
20080254011 | Use of selected lactic acid bacteria for reducing atherosclerosis - Strains of lactic acid bacteria selected for their capability of increasing the BSH-activity and consequently lowering serum LDL-cholesterol, and simultaneously decreasing the pro-inflammatory cytokine TNF-α levels, for prophylaxis and/or treatment of atherosclerosis and other cardiovascular diseases, a method of selecting such strains, and products containing such strains. | 2008-10-16 |
20080254012 | Nutritional Formulation For Promoting Catch-Up Growth - This invention relates to a nutritional formulation comprising an n3 long-chain polyunsaturated fatty acid (LC-PUFA), a prebiotic fibre and a probiotic bacterial strain which ingredients act together in a synergistic fashion to promote catch-up growth in young mammals whose growth has been retarded because the young mammal has been subjected to physical or mental stress. | 2008-10-16 |
20080254013 | Method of Reducing Nematode Damage - A method of reducing damage to plant propagation material and plant organs which grow at a later time by a representative of the class Nematode, which method comprises (I) treating the propagation material with (A) a chelating agent, and optionally (B) a macrocyclic lactone compound or another pesticide, before the material is sown or planted, or (II) applying (A) a chelating agent, and optionally (B) a macrocyclic lactone compound or another pesticide, to the locus of the material or the treated material defined in (I) before its planting, and/or at its planting and/or during its growth. | 2008-10-16 |
20080254014 | Use of Recombinant Yeast Strain Producing an Anti-Inflammatory Compound to Treat Colitis - An administration strategy is disclosed for the delivery at the intestinal mucosa of anti-inflammatory compounds, preferably acid-sensitive anti-inflammatory agents, such as IL10 and/or a soluble TNF receptor and/or trefoil factor via the oral route. In particular, inoculation with a suspension of live recombinant yeast cells, preferably | 2008-10-16 |
20080254015 | Gel Composition of Citrus Complex Carbohydrates Cross-Linked with Cellulose Derivate - A gel for application to a wound, comprising a mixture of citrus complex carbohydrates, a cellulose derivative, a polyol component and water, wherein said citrus complex carbohydrates are cross-linked to said cellulose derivative by an ionic cross-linking agent. | 2008-10-16 |
20080254016 | Composition For Increasing Anti-Oxidation Activity In Blood - The present invention provides a composition capable of maintaining antioxidative activity in blood high by keeping the reduced coenzyme Q | 2008-10-16 |
20080254017 | Methods and compositions for treating symptomes of diseases related to imbalance of essential fatty acids - The invention as disclosed herein provides pharmaneutical compositions and methods for treating, ameliorating, or preventing the symptoms of fatty acids imbalance and cell membrane dysfunction. The pharmaneutical compositions of the invention contain in an effective amount a first and a second composition, the first composition comprises an effective amount of one or more phosphatidylcholine formulations and the second composition comprises an effective amount of one or more constituents comprising essential fatty acid supplements, trace minerals, phenylbutyrate, electrolytes, methylating agents, reduced glutathione, or a combination thereof, in a suitable carrier. | 2008-10-16 |
20080254018 | IMMOBILIZED ANGIOGENIN MIXTURES AND USES THEREOF - Stabilized angiogenin compositions and methods of preparing a stabilized angiogenin compositions by covalent immobilization on a naturally occurring substrate, such as a polysaccharide substrate, are disclosed. In particular, the polysaccharide substrate includes galactose-rich polysaccharide. | 2008-10-16 |
20080254019 | Therapeutic Agents and Therapeutic Methods For Treating Injured Tissue - This invention provides therapeutic agents, transplants and therapeutic methods that can enhance the regeneration of injured tissue. This invention relates to agents, transplants and therapeutic methods for enhancing the migration and accumulation of mesenchymal stem cells in injured tissues and/or suppressing the diffusion of mesenchymal stem cells from injured tissues. | 2008-10-16 |
20080254020 | Therapeutic Peptides - The invention relates to compounds that exhibit improved bioefficacy in multidose administration. More specifically, the invention relates to polypeptides or peptides modified to include an antibody Fc region and one or more water soluble polymers. | 2008-10-16 |
20080254021 | TIE1-BINDING LIGANDS - Tie1 is a receptor tyrosine kinase protein that includes a transmembrane domain. Tie1 is present on endothelial cells. This disclosure described antibodies that bind to Tie1, including ones that inhibit endothelial cell activity. | 2008-10-16 |
20080254022 | Method of Treating Airway Diseases With Beta-Adrenergic Inverse Agonists - The use of β-adrenergic inverse agonists provides a new and highly efficient way of treating a number of pulmonary airway diseases, including asthma, emphysema, and chronic obstructive pulmonary diseases. In general, such a method comprises administering a therapeutically effective amount of a β-adrenergic inverse agonist to the subject to treat the pulmonary airway disease. Particularly preferred inverse agonists include nadolol and carvedilol. | 2008-10-16 |
20080254023 | Treating Gliosis, Glial Scarring, Inflammation or Inhibition of Axonal Growth in the Nervous System by Modulating Eph Receptor - The present invention relates to a method of treating disorders of the nervous system and more particularly disorders associated with a gliotic response and/or an inflammatory response within the central nervous system and to therapeutic agents useful for same. More particularly, the present invention involves a method of preventing or reducing the amount of Eph receptor-mediated gliosis and/or glial scarring and/or inflammation and/or Eph receptor-mediated inhibition of axonal growth which occurs during and/or after disease or injury to the nervous system. The present invention also facilitates the identification of therapeutic agents which modulate Eph receptor-mediated signaling. The method and therapeutic agents of the present invention are useful for treating a range of nervous system diseases, conditions and injuries including, inter alia, paralysis induced by physiological-, pathological- or trauma-induced injury to the brain or spinal cord. | 2008-10-16 |
20080254024 | ANTI-EPHB2 ANTIBODIES AND METHODS USING SAME - The invention provides anti-EphB2 antibodies, immunoconjugates, and compositions comprising and methods of using these antibodies and immunoconjugates. | 2008-10-16 |
20080254025 | Human IL-1 epsilon DNA and polypeptides - The invention is directed to purified and isolated novel human IL-1 epsilon polypeptides, the nucleic acids encoding such polypeptides, processes for production of recombinant forms of such polypeptides, antibodies generated against these polypeptides, the use of such polypeptides in cellular and immune reactions, the use of such polypeptides in screening for agonists or antagonists of IL-1 epsilon activity, and kits comprising such polypeptides. | 2008-10-16 |
20080254026 | ANTAGONIST ANTI-CD40 MONOCLONAL ANTIBODIES AND METHODS FOR THEIR USE - Compositions and methods of therapy for treating diseases mediated by stimulation of CD40 signaling on CD40-expressing cells are provided. The methods comprise administering a therapeutically effective amount of an antagonist anti-CD40 antibody or antigen-binding fragment thereof to a patient in need thereof. The antagonist anti-CD40 antibody or antigen-binding fragment thereof is free of significant agonist activity, but exhibits antagonist activity when the antibody binds a CD40 antigen on a human CD40-expressing cell. Antagonist activity of the anti-CD40 antibody or antigen-binding fragment thereof beneficially inhibits proliferation and/or differentiation of human CD40-expressing cells, such as B cells. | 2008-10-16 |
20080254027 | Optimized CD5 antibodies and methods of using the same - The present invention describes antibodies that target CD5, wherein the antibodies comprise at least one modification relative to a parent antibody, wherein the modification alters affinity to an FcγR or alters effector function as compared to the parent antibody. Also disclosed are methods of using the antibodies of the invention. | 2008-10-16 |
20080254028 | CASPASE-8 BINDING PROTEIN, ITS PREPARATION AND USE - The present invention relates to a caspase-8 interacting polypeptide (Cari), methods for its preparation, and its use. | 2008-10-16 |
20080254029 | Use of an Inhibitor of TNFa Plus an Antihistamine to Treat Allergic Rhinitis and Allergic Conjunctivitis - Disclosed are methods of treating allergic conjunctivitis and allergic rhinitis in a subject that involve topically administering to the subject a composition comprising a pharmaceutically effective amount of an H | 2008-10-16 |
20080254030 | Use of Baff to Treat Th2-Mediated Conditions - Compositions and methods for treating Th2-mediated disease are provided. | 2008-10-16 |
20080254031 | Tumor Specific Genes and Variant Rnas and Uses Thereof as Targets for Cancer Therapy and Diagnosis - Genes and variant RNAs that are differentially expressed in human colon tumor tissues compared with normal colon tissue and the corresponding proteins are identified. These genes and the corresponding antigens are suitable targets for the treatment, diagnosis or prophylaxis of colon cancer. | 2008-10-16 |
20080254032 | Antibodies to M-CSF - The present invention relates to antibodies and antigen-binding portions thereof that specifically bind to a M-CSF, preferably human M-CSF, and that function to inhibit a M-CSF. The invention also relates to human anti-M-CSF antibodies and antigen-binding portions thereof. The invention also relates to antibodies that are chimeric, bispecific, derivatized, single chain antibodies or portions of fusion proteins. The invention also relates to isolated heavy and light chain immunoglobulins derived from human anti-M-CSF antibodies and nucleic acid molecules encoding such immunoglobulins. The present invention also relates to methods of making human anti-M-CSF antibodies, compositions comprising these antibodies and methods of using the antibodies and compositions for diagnosis and treatment. The invention also provides gene therapy methods using nucleic acid molecules encoding the heavy and/or light immunoglobulin molecules that comprise the human anti-M-CSF antibodies. The invention also relates to transgenic animals and transgenic plants comprising nucleic acid molecules of the present invention. | 2008-10-16 |
20080254033 | Pharmaceutical Compositions Containing Antagonists to Lrp4, Lrp8 or Megalin for Treatment of Diseases - The present invention provides LRP4, LRP8 and LRP2 (megalin) polypeptides; polynucleotides encoding such; modulators of LRP4, LRP8 and LRP2 activity; and pharmaceutical compositions for the treatment of diseases. Compositions of the invention contain a pharmaceutically acceptable carrier or excipient and at least one modulator that is capable of binding to or interfering with the activity of LRP4, LRP8, LRP2 and active fragments thereof. The invention provides modulators, such as antibodies, RNAi molecules, anti-sense molecules and ribozymes. Additionally, the invention includes methods for the treatment of diseases, such as proliferative diseases and degenerative diseases, and methods of administration of the compositions of the invention. | 2008-10-16 |
20080254034 | BASB119 Polypeptide and Polynucleotide from Moraxella Catarrhalis - The invention provides BASB119 polypeptides and polynucleotides encoding BASB119 polypeptides and methods for producing such polypeptides by recombinant techniques. Also provided are diagnostic, prophylactic and therapeutic uses. | 2008-10-16 |
20080254035 | Lipocalin Protein - The invention is based on the discovery that the human protein referred to herein as INSP181 protein is a lipocalin. | 2008-10-16 |
20080254036 | COMBINATION ANTICOAGULANT THERAPY WITH A COMPOUND THAT ACTS AS A FACTOR XA INHIBITOR - The present invention is directed to methods of using combination therapies containing [2-({4-[(dimethylamino)iminomethyl]phenyl}carbonylamino)-5-methoxyphenyl]-N-(5-chloro(2-pyridyl))carboxamide for the treatment of thrombotic disease(s) and pharmaceutical compositions thereof. | 2008-10-16 |
20080254037 | METHOD OF TREATING ISCHEMIA REPERFUSION INJURY BY INHIBING NKT CELL ACTIVITY - The present invention relates to a method for treating recurrent tumor metastases following liver resection that includes administration of an effective amount of an agonist of A | 2008-10-16 |
20080254038 | Immunogen adherence inhibitor directed to lactobacillus organisms and method of making and using it - A microbial adherence inhibitor specific to lactic acid producing microorganisms, in the form of fowl egg antibodies is disclosed, along with the method of making it and methods of using it. The inhibitor functions by substantially preventing the attachment or adherence of colony-forming immunogens in the fermentators. The inhibitor is made by inoculating female birds with the immunogen, allowing time for an immune response in the female bird and then harvesting the eggs that contain antibodies to the immunogen. The egg contents can be dried or used as a liquid and added to the media in the fermentators. Dependent upon the particular immunogen with which the female bird is inoculated, the egg antibody will specifically bind to the specific immunogen. When bacteria such as | 2008-10-16 |
20080254039 | Prevention of Thrombus Formation and/or Stabilization - The present invention relates to the use of at least one antibody and/or one inhibitor for inhibiting factor XII and preventing the formation and/or the stabilization of three-dimensional thrombi. It also relates to a pharmaceutical formulation and the use of factor XII as an anti-thrombotic target. | 2008-10-16 |
20080254040 | COMBINATIONS FOR THE TREATMENT OF DISEASES INVOLVING CELL PROLIFERATION, MIGRATION OR APOPTOSIS OF MYELOMA CELLS OR ANGIOGENESIS - The present invention relates to a pharmaceutical combination for the treatment of diseases which involves cell proliferation, migration or apoptosis of myeloma cells, or angiogenesis. The invention also relates to a method for the treatment of said diseases, comprising co-administration of effective amounts of specific active compounds and/or co-treatment with radiation therapy, in a ratio which provides an additive and synergistic effect, and to the combined use of these specific compounds and/or radiotherapy for the manufacture of corresponding pharmaceutical combination preparations. | 2008-10-16 |
20080254041 | Method for Selecting an Immunotherapeutic Preparation - The present invention relates to a method for selecting one or more immunotherapeutic preparation having improved properties as a vaccine against a target antigen, said method comprising raising antibodies against a group of candidate preparations and selecting one or more preparations which produces antibodies having higher affinity against the target antigen than does anti-bodies raised against at least one other preparation from the group. More particularly it relates to the need to provide recombinant allergens (Bet V 1) for SIT which have been modified by protein engineering. | 2008-10-16 |
20080254042 | Novel Use of Prrp and Receptor Thereof - The present invention relates to provision of a method of screening a medicament using a disease-associated gene product, an antibody to the disease-associated gene product, and an antisense DNA which suppresses expression of the disease-associated gene product. Specifically, the present invention provides a protein comprising the same or substantially the same amino acid sequence as the amino acid sequence represented by SEQ ID NO: 1, its partial peptide, or a salt thereof. | 2008-10-16 |